Correspondence 0001193125-23-202432 from Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Aug. 3, 2023 · CIK: 0001808898 · Accession: 0001193125-23-202432
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273177
Letter
Re: Benitec Biopharma Inc.
August 3, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-1004
Registration Statement on Form S-1, as amended
File No. 333-273177
Ladies and Gentleman:
As the underwriter of the proposed offering of Benitec Biopharma Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:30 p.m., Eastern Time, on Monday, August 7, 2023, or as soon thereafter as is practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, acting on behalf of the several underwriters, wish to advise you that, through August 3, 2023, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated August 3, 2023, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Citizens JMP Securities, LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 3, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Benitec Biopharma Inc. Registration Statement on Form S-1, as amended File No. 333-273177 Ladies and Gentleman: As the underwriter of the proposed offering of Benitec Biopharma Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:30 p.m., Eastern Time, on Monday, August 7, 2023, or as soon thereafter as is practicable. Pursuant to Rule 460 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, we, acting on behalf of the several underwriters, wish to advise you that, through August 3, 2023, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated August 3, 2023, as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, Citizens JMP Securities, LLC By: /s/ Andrew Mertz Name: Andrew Mertz Title: Managing Director, Head of Equity Capital Markets